| 21.03 0.19 (0.91%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.24 | 1-year : | 26.31 |
| Resists | First : | 21.61 | Second : | 22.53 |
| Pivot price | 21  |
|||
| Supports | First : | 20.12 | Second : | 16.74 |
| MAs | MA(5) : | 20.96 |
MA(20) : | 21.12 |
| MA(100) : | 17.02 |
MA(250) : | 13.41 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 43.2 |
D(3) : | 41.3 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 22.87 | Low : | 8.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ANIK ] has closed below upper band by 46.1%. Bollinger Bands are 73.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 21.35 - 21.47 | 21.47 - 21.58 |
| Low: | 20.61 - 20.77 | 20.77 - 20.91 |
| Close: | 20.8 - 21.03 | 21.03 - 21.24 |
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Tue, 08 Sep 2026
Anika Therapeutics (ANIK) Retreats 1.06% as Shares Hold Above Key $19.56 Support - Wave Extension - siam.in
Fri, 21 Aug 2026
Anika Therapeutics Inc (NASDAQ: ANIK) Share Price, ANIK Stock News, ANIK Share Price & Updates - kalkine.ca
Fri, 21 Aug 2026
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why? - Yahoo Finance
Fri, 14 Aug 2026
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know - Yahoo Finance
Fri, 07 Aug 2026
ANIK (NASDAQ: ANIK) holder plans Form 144 sale of 16,864 shares - Stock Titan
Wed, 29 Jul 2026
Anika Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 13 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 93.4 (%) |
| Shares Short | 337 (K) |
| Shares Short P.Month | 350 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.26 |
| Profit Margin | -3.2 % |
| Operating Margin | 11.4 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | -2.2 % |
| Qtrly Rev. Growth | 15.6 % |
| Gross Profit (p.s.) | 5.6 |
| Sales Per Share | 9.01 |
| EBITDA (p.s.) | 0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 6 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -91.44 |
| PEG Ratio | 2.2 |
| Price to Book value | 2.04 |
| Price to Sales | 2.33 |
| Price to Cash Flow | 47.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|